Advertisements

Olynth 0.05%

Quick links to important sections

Olynth 0.05%

Advertisements

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Olynth 0.05%

What is Olynth 0.05%? Definitional Overview

Property Description
Active ingredient Xylometazoline hydrochloride
Form Nasal solution (Spray/Drops)
Pharmacological class Sympathomimetic agent, alpha-Adrenergic Agonist
General purpose Decongestant (relief of stuffiness)
Origin Synthetic compound (Imidazoline derivative)

What is Xylometazoline and its Pharmacological Class?

Olynth 0.05% is a medicinal product defined by its sole active pharmaceutical ingredient, Xylometazoline hydrochloride, which is formulated as an aqueous nasal solution for topical administration. This compound is chemically categorized as a synthetic imidazoline derivative, which places it in the pharmacological class of sympathomimetic agents. The mechanism of Xylometazoline is clinically recognized as a direct-acting alpha-adrenergic agonist, a function often noted in official pharmaceutical listings. Olynth is typically positioned as an over-the-counter (OTC) medicine, distinguished by its concentration being specifically tailored for different age groups. This classification dictates the product's primary use in providing highly localized relief from nasal congestion.


Olynth 0.05% as a Decongestant Nasal Solution

The general purpose of the Olynth 0.05% preparation is to function as a powerful, localized decongestant aimed at alleviating the sensation of nasal stuffiness or blockage, a typical use scenario during a common cold. This effect is achieved through the primary physiological action of vasoconstriction, where the active component causes the small blood vessels in the nasal mucosa to contract. The resultant effect is a significant reduction in the swelling of the nasal lining, which is the physical cause of congestion. The 0.05% concentration is specifically formulated for the pediatric population (children 2 to 12 years of age), representing a necessary lower strength compared to adult-specific preparations. Xylometazoline quickly reduces swelling in the nasal passages. This means the medicine helps temporarily restore easier breathing by rapidly shrinking swollen tissues. This form of administration, typically via a nasal spray or drops, ensures the decongestant effect is targeted and rapid.

Advertisements

What side effects are possible with Olynth 0.05%?

Possible Side Effects and Safety Information

Official regulatory documents classify the possible adverse reactions of Xylometazoline 0.05% based on their expected frequency. The safety profile is defined by both local and systemic effects, consistent with its classification as a sympathomimetic agent.

Frequency-Classified Adverse Reactions

  • Common: Reactions occurring most frequently include stinging or burning sensation in the nose and throat, nasal dryness (dry nasal mucous membranes), sneezing, headache, and nausea.
  • Uncommon: Less frequent effects include hypersensitivity reactions (such as rash or pruritus), epistaxis (nosebleed), and increased swelling of the nasal mucosa after stopping treatment, a phenomenon known as rebound congestion.
  • Rare to Very Rare: Serious or less frequent systemic reactions include palpitations, tachycardia (increased heart rate), and hypertension. Very rarely, effects on the nervous system like dizziness and insomnia are documented.

Systemic and Population-Specific Safety Patterns

Adverse reactions are reported across several System-Organ Classes (SOCs), most notably Respiratory, Thoracic and Mediastinal Disorders for local effects, and Cardiac and Vascular Disorders for systemic effects.

Regulatory labels include population-specific safety considerations for the target age group of this concentration. Systemic effects such as convulsions, sleepiness, or hallucinations are noted as very rare events occurring mainly in children. Furthermore, apnoea (cessation of breathing) is classified as a very rare and serious risk in infants and neonates.

Time-Related Safety Patterns document that the risk of rebound congestion and atrophy of the nasal mucosa is associated with prolonged or excessive use. High-level safety constraints are stated for patients with pre-existing conditions like severe cardiovascular disorders or rhinitis sicca, and caution is advised regarding use alongside medications like MAO inhibitors, due to the potential for blood pressure increases.

Advertisements

Overdose and Emergency Response

The official regulatory profile for Xylometazoline overdose describes manifestations primarily affecting the central nervous system (CNS) and the cardiovascular system. Overdose may present with an initial period of CNS stimulation (agitation, fear, hallucinations) often followed by severe CNS depression (drowsiness, lethargy, or coma). Cardiovascular instability is documented, including significant fluctuations such as bradycardia (slow heart rate) or tachycardia (fast heart rate), and blood pressure changes (initial hypertension followed by profound hypotension), which carry the risk of cardiovascular collapse. Other documented signs include hypothermia, pallor, and convulsions, particularly in children.

The official labeling identifies infants and neonates as especially vulnerable, where overdose can result in life-threatening complications like serious CNS depression and apnoea (cessation of breathing). Consequently, regulatory bodies mandate that emergency medical care must be sought immediately following any suspected accidental ingestion, requiring immediate contact with a poison control center or emergency services. Treatment is symptomatic and supportive, involving monitoring of vital signs and ECG. No specific antidote is stated in the available regulatory documents. Hospital observation is required due to the potential severity of the systemic effects.

Advertisements

Therapeutic Uses of Olynth 0.05%

Main Indications and Therapeutic Uses

Olynth 0.05% is a nasal decongestant formulated for children between the ages of 2 and 6 years. It is primarily used to provide temporary relief from nasal congestion associated with several respiratory conditions.

Nasal Congestion Relief

The primary function of the solution is to reduce the swelling of the nasal mucosa. This is particularly relevant in the following cases:

  • Common Cold and Rhinitis: It helps alleviate the "stuffy nose" sensation caused by viral or bacterial infections of the upper respiratory tract.
  • Allergic Rhinitis: It can be used to manage acute episodes of nasal congestion triggered by hay fever or other airborne allergens.
  • Sinusitis: By reducing swelling at the openings of the paranasal sinuses, it may facilitate the drainage of secretions and ease the feeling of pressure.

Additional Uses

In certain clinical contexts, the solution may be used to support the management of specific middle ear conditions:

  • Otitis Media: In cases of inflammation of the middle ear, the product may be used as a supportive treatment to decongest the nasopharyngeal mucosa, which helps in opening the Eustachian tube.
  • Diagnostic Procedures: It is sometimes applied to facilitate rhinoscopy or other nasal examinations by providing a clearer view of the nasal passages.

Expected Benefits and Mechanism

Rapid Onset of Action

The active ingredient acts locally on the blood vessels within the nasal lining. Upon application, it causes these vessels to constrict, which leads to a visible reduction in swelling of the mucous membrane. This process typically begins within five to ten minutes after administration.

Improved Nasal Airflow

By decreasing the volume of the swollen tissue, the diameter of the nasal passages is increased. This allows for easier breathing through the nose and can help reduce the discomfort associated with mouth breathing during periods of illness.

Duration of Effect

The formulation is designed to provide prolonged relief, often lasting for several hours, which can be particularly beneficial for improving rest and comfort during recovery from respiratory infections.

Regulatory References

  1. Public Assessment Report
Advertisements

Eligibility and Restrictions for Use

Official Eligibility for Olynth 0.05% (Xylometazoline HCl)

Official regulatory documents define the population eligibility for Olynth 0.05% by age, existing health conditions, and physiological status.

Eligibility Group Regulatory Status
Children 2 to 10 years Approved (standard labeled population for 0.05% strength).
Infants/Children under 2 years Contraindicated/Not Recommended (varies by label; use is not established).
Pregnancy Should be avoided as a precaution due to the vasoconstrictor properties.
Lactation/Breastfeeding Use only on the advice of a doctor (data on excretion is not established).

Absolute Contraindications (Must Not Use): The medicine is formally contraindicated in patients with known hypersensitivity to the active substance, narrow-angle glaucoma, rhinitis sicca (atrophic rhinitis), and history of surgery exposing the dura mater (e.g., trans-sphenoidal hypophysectomy).

Conditional Use (Use with Caution): Use requires caution in patients with hypertension, severe cardiovascular disorders (including Long QT syndrome), diabetes mellitus, hyperthyroidism, and in those taking Monoamine Oxidase Inhibitors (MAOIs) or who have taken them within the last 14 days.

Advertisements

What should I know about interactions with other medicines?

The official regulatory interaction profile for Xylometazoline hydrochloride focuses exclusively on pharmacodynamic interactions with medicines that affect blood pressure and the sympathetic nervous system.

Contraindicated Combinations and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is classified as a contraindicated combination by regulatory authorities. This severe restriction is due to the documented risk of a hypertensive crisis resulting from the potentiation of the drug’s sympathomimetic effects. A mandatory timing rule further applies: the product must not be used if a patient has taken an MAOI within the last 14 days before administration.

Pharmacodynamic Interactions

Official labels warn that concurrent use with Tricyclic or Tetracyclic Antidepressants can result in an intensification of the sympathomimetic effect, which may lead to potentiated pressor effects. Similarly, combining Xylometazoline with other sympathomimetic agents is documented to produce additive sympathetic effects, potentially increasing both blood pressure and heart rate.

Cardiovascular System Relevance

The regulatory profile notes caution when Xylometazoline is used alongside certain cardiovascular medicines. Because it is an alpha-adrenergic agonist, the product may impact blood pressure regulation. This constraint is relevant for patients also taking drugs such as Anti-hypertensives or Cardiac Glycosides. The regulatory documentation contains no official statements regarding interactions with food, alcohol, herbal products, or specific metabolic enzymes.

Advertisements

Mechanism of Action

Olynth 0.05% (Xylometazoline) functions as an alpha-adrenergic receptor agonist. Its action is initiated by the selective binding and activation of alpha2-adrenergic receptors. These receptors are specifically located on the smooth muscle cells that line the vasculature within the nasal mucosa.

The activation of the alpha2-adrenergic receptors triggers an immediate intracellular signaling cascade typically involving the inhibition of adenylyl cyclase and subsequent modulation of cyclic AMP (cAMP) levels. This G protein-coupled signaling ultimately leads to the rapid vasoconstriction of arterioles in the targeted tissue. The resulting decrease in localized blood flow serves to modulate the fluid volume in the surrounding tissue, leading to a physiological reduction of mucosal swelling. This sequence constitutes the entirety of the pharmacodynamic mechanism.

Advertisements

Dosage and Administration Information

Administration Guidelines for Olynth 0.05%

Olynth 0.05% (Xylometazoline Hydrochloride 0.05% w/v) is a medication formulated for intranasal use only. The 0.05% concentration is intended for use in children aged 2 to 12 years. Adherence to the stated dosing and duration limits is important to ensure proper use and to prevent complications.


Dosing and Administration Schedule

Item Instruction
Route of Administration Intranasal use (Nasal) only
Target Population (0.05%) Children aged 2 to 12 years
Standard Dose 1 to 2 applications (drops or metered sprays) into each nostril
Maximum Frequency Up to 3 times per 24-hour period, as needed
Course Duration Must not be used for longer than 5 to 7 consecutive days

Procedural Steps for Use

  1. Preparation: The nose should be thoroughly cleared before application. If using the spray form, the pump must be primed before the first use (or after a prolonged break) until a fine, uniform mist is emitted.
  2. Application: Insert the nozzle or dropper into the nostril. Apply the prescribed dose while inhaling gently through the nose. Repeat the process in the other nostril.
  3. Frequency Control: Adhere to the minimum time interval between doses; the total number of applications must not exceed three per day in each nostril.
  4. Device Restriction: The medication should only be used by one person to prevent the spread of infection.

This protocol dictates the standardized method of use, ensuring the correct strength is applied to the intended population for the limited time frame.

Advertisements

Recent Clinical Evidence

Olynth 0.05%: Recent Clinical Evidence

Mechanism and Primary Studies

Olynth 0.05% contains xylometazoline hydrochloride, an alpha-adrenergic agonist, which functions as a topical nasal decongestant. Its use is based on the compound’s ability to cause vasoconstriction (narrowing of blood vessels) in the nasal lining, aiming to reduce swelling and facilitate improved airflow. The formulation is primarily studied for the temporary symptomatic relief of nasal congestion associated with rhinitis (including the common cold) and sinusitis.


Efficacy and Duration of Action

Clinical trials, including randomized controlled studies, have assessed the decongestant effect of xylometazoline 0.05% against a placebo (saline solution) in subjects with nasal congestion. Objective measurements, such as nasal conductance, have demonstrated significant changes in nasal airflow compared to placebo. Studies have consistently reported rapid onset of action, often within a few minutes, and a sustained effect that may last for up to 10 to 12 hours following administration.


Safety and Tolerability Profile

The safety profile of xylometazoline has been extensively documented over its long-established use. The most commonly reported side effects observed in clinical settings are typically localized to the nasal area and may include dryness, burning, or mild irritation of the nasal mucosa, as well as sneezing or headache.

Research emphasizes that prolonged or excessive use of topical nasal decongestants may be associated with rebound congestion (rhinitis medicamentosa) upon discontinuation. This finding underscores the importance of adhering to recommended short-term usage guidelines. Studies involving combination sprays (e.g., with dexpanthenol or lysozyme) have also explored methods to potentially improve mucosal tolerability while maintaining decongestant effect.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Olynth 0.05% (FAQ)

Q: How quickly should I expect Olynth 0.05% to start working after I use it?

A: Studies and official product information indicate that the product is designed for rapid relief of congestion. The onset of its decongestant effect is commonly reported to occur rapidly, often within a few minutes (e.g., 2 to 5 minutes) of administration.

Q: How long does the relief from Olynth 0.05% usually last?

A: The decongestant effect of Olynth 0.05% is designed to be sustained. According to official labeling, the relief may typically last for an extended period, generally up to 10 to 12 hours following a single application.

Q: Is Olynth 0.05% safe for use during pregnancy, according to available information?

A: Regulatory documents state that due to its known properties as a vasoconstrictor (causing blood vessels to narrow), Olynth 0.05% should generally be avoided during pregnancy as a precaution. Regulatory warnings state that use should occur only under the explicit guidance of a healthcare professional.

Q: Can I use Olynth 0.05% with other cold or flu medications?

A: Official warnings focus on the risk of using this product with other medications that increase heart rate or blood pressure, including other sympathomimetic agents. Many common cold and flu medications contain decongestants that are also sympathomimetics, which could cause additive effects. Consultation with a healthcare professional is recommended before combining them.

Q: What should I do if I accidentally swallow a small amount of Olynth 0.05%?

A: If the medicine is swallowed inadvertently, especially by a child, there is a risk of symptoms affecting the central nervous system (CNS), such as drowsiness or a marked reduction in body temperature. If accidental ingestion or overdose is suspected, medical help should be sought immediately, particularly if symptoms of CNS depression are observed.

Q: Can using Olynth 0.05% make me feel jittery or cause palpitations?

A: Because this medicine is a type of sympathomimetic agent, it can sometimes affect the cardiovascular system. Rare side effects documented in official labeling include palpitations (feeling your heart beat rapidly or irregularly) and tachycardia (increased heart rate). Systemic effects may also rarely cause feelings of jitteriness or restlessness.

Q: How should Olynth 0.05% be stored, and does it expire quickly once opened?

A: Olynth 0.05% must be stored according to package instructions, often below 25 C or 30 C. Once the container is opened, the product has a limited shelf life. Official guidelines state it must be discarded after a specific period, typically 28 days or 12 weeks, depending on the formulation, to maintain quality and avoid contamination.

Q: What is the mechanism of action for Olynth 0.05%—how does it clear the nose?

A: Olynth 0.05% works by delivering an active substance that acts as a topical vasoconstrictor. This means it causes the small blood vessels in the lining of the nose to narrow. This action reduces the localized blood flow and rapidly shrinks the swollen nasal mucosa, which is what clears the nose and relieves congestion.

Q: Is Olynth 0.05% different from similar-sounding nasal sprays like Otrivin or Xylometazolin?

A: Olynth 0.05% is a brand name for a nasal solution containing the active ingredient Xylometazoline hydrochloride 0.05%. Therefore, it contains the same active drug as other products also containing Xylometazoline. While the core drug is the same, regulatory documents note that other brand names may use slightly different inactive ingredients or formulations.

Q: Can Olynth 0.05% be used while breastfeeding?

A: Official information states that it is unknown if the active substance is excreted in human milk. Therefore, use during breastfeeding is generally not recommended. If considering use while breastfeeding, the product labeling notes that a healthcare professional’s specific advice is required.

Q: Does Olynth 0.05% work for congestion caused by a dry environment?

A: The product is officially indicated for the symptomatic relief of nasal congestion associated with conditions like rhinitis (inflammation of the nasal passages). Since its mechanism involves reducing mucosal swelling, its use may provide temporary symptomatic relief from congestion caused by various factors, including environmental dryness.

Q: Does Olynth 0.05% contain any preservatives that people should be aware of?

A: Yes, official labeling lists the full set of ingredients. Olynth 0.05% typically contains an excipient (inactive ingredient) such as benzalkonium chloride as a preservative. This excipient is noted in the labeling because it may rarely cause local irritation or allergic reactions in sensitive individuals.

Q: Are there known cases of allergic reactions to Olynth 0.05%?

A: Yes, official regulatory documents list hypersensitivity reactions as a known side effect, though they are uncommon. Hypersensitivity to the active substance or any of the inactive ingredients is listed as a formal contraindication, meaning the product must not be used by individuals with a known allergy to its components.

Q: Is Olynth 0.05% habit-forming, and what does that really mean?

A: The product is not typically classified as habit-forming in the traditional sense, but official warnings emphasize the risk of rebound congestion or rhinitis medicamentosa. This occurs when the congestion returns or worsens immediately after the product wears off, leading users to feel they need to use the product continuously. This is the reason usage is limited to a strict short period.

Q: Is it safe to drive or operate machinery after using Olynth 0.05%?

A: When the product is used correctly at the recommended short-term dose, official regulatory information indicates there are generally no known effects on the ability to drive or use machines. However, if you experience rare systemic side effects like dizziness or insomnia, your ability to perform these tasks may be impaired.

Q: What are the signs of using Olynth 0.05% too frequently?

A: The primary sign of overuse is the phenomenon of rebound congestion, where the nasal passages become more swollen and blocked after the effects of the dose wear off. If use continues excessively, regulatory documents note rare risks of chronic changes to the nasal lining, such as dryness or atrophy of the nasal mucosa.

Q: Is Olynth 0.05% used for chronic sinus issues or just short-term relief?

A: Olynth 0.05% is strictly indicated for short-term symptomatic relief of nasal congestion. Regulatory documents specifically warn that prolonged or chronic use of this type of vasoconstrictor is not appropriate for long-term conditions due to the risk of mucosal damage and rebound congestion.

Q: Are there specific studies or research that back up the effectiveness of Olynth 0.05%?

A: Yes, the effectiveness of the product is supported by clinical studies. These include randomized controlled trials that compare the decongestant effect to a placebo and provide objective measurements demonstrating improved nasal airflow.

Q: How does the action of Olynth 0.05% differ from oral decongestant pills?

A: The action of Olynth 0.05% is topical and highly localized, meaning it acts directly on the blood vessels in the nose with minimal absorption into the rest of the body. Oral decongestant pills, in contrast, have a systemic effect, circulating throughout the entire body. This difference is relevant because systemic drugs may have a higher risk of systemic side effects.

Q: What components in Olynth 0.05% help with moisturizing the nasal passages?

A: The product is formulated with inactive ingredients (excipients) that help with the stability and application of the solution. Regulatory labels note components like sorbitol and potentially other agents that are included in the formulation to possibly improve the overall tolerability and mucosal comfort during use.

Q: Is there a maximum number of times I can spray Olynth 0.05% in a single day?

A: Yes, official administration guidelines set a clear limit. The maximum frequency is typically up to 3 times per 24-hour period in each nostril, and this daily total must not be exceeded as part of the safe use protocol.

Q: Is Olynth 0.05% a product that can be used on an as-needed basis?

A: Yes, official administration guidelines state that the product can be applied as needed to relieve congestion. However, the use of Olynth 0.05% is still limited to a strict short-term course, not exceeding 5 to 7 consecutive days.

Q: Why is Olynth 0.05% sometimes described as a topical vasoconstrictor?

A: It is described as a topical vasoconstrictor because of its physiological function. 'Topical' means it is applied directly to the surface (the nasal lining), and 'vasoconstrictor' means it causes the blood vessels (vasculature) in that area to narrow or constrict, which is the exact mechanism that reduces swelling and relieves stuffiness.

Q: Is Olynth 0.05% known to interact with herbal supplements like St. John's Wort?

A: Official regulatory warnings focus on interactions with prescription medicines that affect blood pressure. The official documentation does not contain specific statements regarding interactions with herbal supplements, suggesting data may be limited.

Q: What is the long-term safety profile of the active ingredient in Olynth 0.05%?

A: The regulatory profile stresses that the product is designed for short-term use only. Long-term use is associated with known adverse effects, including the risk of severe rebound congestion and, rarely, chronic structural damage like atrophy of the nasal mucosa. It is not intended for chronic treatment.

Q: Can Olynth 0.05% be used to help a child who is struggling to sleep due to congestion?

A: The product is indicated for the symptomatic relief of nasal congestion and is formulated for children aged 2-12 years. Because it is reported to provide sustained relief for up to 12 hours, using it to clear congestion may indirectly help the child breathe more easily and potentially improve sleep quality.

Advertisements

How should Olynth 0.05% be stored and disposed of?

Official Storage and Disposal Requirements

The storage and disposal of Olynth 0.05% (Xylometazoline hydrochloride) must adhere strictly to regulatory labeling to maintain product stability and ensure environmental safety.

Condition Type Requirement Summary
Temperature and Environment Store below 25 C or 30 C (check specific label). Do not freeze and protect from light and heat.
Container Integrity Keep the medicine in its original container and ensure it is tightly closed when not in use.
Stability after Opening Discard the product after a limited period, typically 28 days or 12 weeks, following the date of first opening.
Child Safety Keep Olynth 0.05% out of the sight and reach of children at all times.
Disposal Instructions Unused or expired medicine must not be disposed of in household waste or wastewater. Dispose of the product according to local requirements, typically by returning it to a pharmacy.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Olynth 0.05% found in:

A-Z Index: